{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:11:13Z","timestamp":1793171473525,"version":"4.5.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T00:00:00Z","timestamp":1490313600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s00392-017-1106-1","type":"journal-article","created":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T15:06:06Z","timestamp":1490367966000},"page":"663-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":216,"title":["HDL cholesterol: reappraisal of its clinical relevance"],"prefix":"10.1007","volume":"106","author":[{"given":"Winfried","family":"M\u00e4rz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus E.","family":"Kleber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Scharnagl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timotheus","family":"Speer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Zewinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Ritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus G.","family":"Parhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"von Eckardstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,24]]},"reference":[{"key":"1106_CR1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","volume":"79","author":"DJ Gordon","year":"1989","unstructured":"Gordon DJ, Probstfield JL, Garrison RJ et al (1989) High density lipoprotein cholesterol and cardiovascular disease. Four Prospective American Studies. Circulation 79:8\u201315","journal-title":"Circulation"},{"issue":"15","key":"1106_CR2","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/0002-9149(91)90924-A","volume":"67","author":"JJ Genest","year":"1991","unstructured":"Genest JJ, McNamara JR, Salem DN, Schaefer EJ (1991) Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 67(15):1185\u20131189","journal-title":"Am J Cardiol"},{"issue":"18","key":"1106_CR3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"E Di Angelantonio","year":"2009","unstructured":"Di Angelantonio E, Sarwar N, Perry P et al (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302(18):1993\u20132000","journal-title":"JAMA"},{"issue":"6","key":"1106_CR4","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jacc.2007.09.060","volume":"51","author":"WA Steeg van der","year":"2008","unstructured":"van der Steeg WA, Holme I, Boekholdt SM et al (2008) High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 51(6):634\u2013642","journal-title":"J Am Coll Cardiol"},{"key":"1106_CR5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00730116","author":"B Bowe","year":"2016","unstructured":"Bowe B, Xie Y, Xian H, Balasubramanian S, Zayed MA, Al-Aly Z (2016) High density lipoprotein cholesterol and the risk of all-cause mortality among US Veterans. Clin J Am Soc Nephrol. doi: 10.2215\/CJN.00730116","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"1106_CR6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1161\/CIRCOUTCOMES.115.002436","volume":"9","author":"J Bartlett","year":"2016","unstructured":"Bartlett J, Predazzi IM, Williams SM et al (2016) Is isolated low high-density lipoprotein cholesterol a cardiovascular disease risk factor? New insights from the Framingham offspring study. Circ Cardiovasc Qual Outcomes 9(3):206\u2013212","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"1106_CR7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00059-016-4499-0","volume":"42","author":"W M\u00e4rz","year":"2017","unstructured":"M\u00e4rz W, Kleber ME, Scharnagl H et al (2017) Clinical importance of HDL cholesterol. Herz 42(1):58\u201366","journal-title":"Herz"},{"issue":"35","key":"1106_CR8","doi-asserted-by":"crossref","first-page":"24020","DOI":"10.1074\/jbc.R114.583658","volume":"289","author":"MC Phillips","year":"2014","unstructured":"Phillips MC (2014) Molecular mechanisms of cellular cholesterol efflux. J Biol Chem 289(35):24020\u201324029","journal-title":"J Biol Chem"},{"key":"1106_CR9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.trsl.2016.02.008","volume":"173","author":"W Annema","year":"2016","unstructured":"Annema W, von Eckardstein A (2016) Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy. Transl Res 173:30\u201357","journal-title":"Transl Res"},{"issue":"7","key":"1106_CR10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.bbalip.2016.03.004","volume":"1861","author":"M Lee-Rueckert","year":"2016","unstructured":"Lee-Rueckert M, Escola-Gil JC, Kovanen PT (2016) HDL functionality in reverse cholesterol transport\u2013Challenges in translating data emerging from mouse models to human disease. Biochim Biophys Acta 1861(7):566\u2013583","journal-title":"Biochim Biophys Acta"},{"issue":"15","key":"1106_CR11","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1161\/CIRCULATIONAHA.111.066589","volume":"125","author":"RS Rosenson","year":"2012","unstructured":"Rosenson RS, Brewer HB Jr, Davidson WS et al (2012) Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125(15):1905\u20131919","journal-title":"Circulation"},{"issue":"11","key":"1106_CR12","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.bbalip.2013.07.014","volume":"1831","author":"C Rohrl","year":"2013","unstructured":"Rohrl C, Stangl H (2013) HDL endocytosis and resecretion. Biochim Biophys Acta 1831(11):1626\u20131633","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"1106_CR13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/11914","volume":"22","author":"M Bodzioch","year":"1999","unstructured":"Bodzioch M, Orso E, Klucken J et al (1999) The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 22(4):347\u2013351","journal-title":"Nat Genet"},{"issue":"4","key":"1106_CR14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/11921","volume":"22","author":"S Rust","year":"1999","unstructured":"Rust S, Rosier M, Funke H et al (1999) Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 22(4):352\u2013355","journal-title":"Nat Genet"},{"issue":"1","key":"1106_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.08.002","volume":"209","author":"EC Quintao","year":"2010","unstructured":"Quintao EC, Cazita PM (2010) Lipid transfer proteins: past, present and perspectives. Atherosclerosis 209(1):1\u20139","journal-title":"Atherosclerosis"},{"issue":"10","key":"1106_CR16","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/clinchem\/41.10.1414","volume":"41","author":"PS Bachorik","year":"1995","unstructured":"Bachorik PS, Ross JW (1995) National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 41(10):1414\u20131420","journal-title":"Clin Chem"},{"issue":"9","key":"1106_CR17","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/clinchem\/47.9.1579","volume":"47","author":"GR Warnick","year":"2001","unstructured":"Warnick GR, Nauck M, Rifai N (2001) Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem 47(9):1579\u20131596","journal-title":"Clin Chem"},{"issue":"25","key":"1106_CR18","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG, Langsted A, Mora S et al (2016) Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 37(25):1944\u20131958","journal-title":"Eur Heart J"},{"issue":"6","key":"1106_CR19","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1373\/clinchem.2009.142810","volume":"56","author":"WG Miller","year":"2010","unstructured":"Miller WG, Myers GL, Sakurabayashi I et al (2010) Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem 56(6):977\u2013986","journal-title":"Clin Chem"},{"issue":"1","key":"1106_CR20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.atherosclerosis.2013.12.033","volume":"233","author":"T Miida","year":"2014","unstructured":"Miida T, Nishimura K, Okamura T et al (2014) Validation of homogeneous assays for HDL-cholesterol using fresh samples from healthy and diseased subjects. Atherosclerosis 233(1):253\u2013259","journal-title":"Atherosclerosis"},{"issue":"1","key":"1106_CR21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2013.12.016","volume":"233","author":"MR Langlois","year":"2014","unstructured":"Langlois MR, Descamps OS, van der Laarse A et al (2014) Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. Atherosclerosis 233(1):83\u201390","journal-title":"Atherosclerosis"},{"issue":"1","key":"1106_CR22","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1373\/clinchem.2015.246702","volume":"62","author":"I Broek van den","year":"2016","unstructured":"van den Broek I, Romijn FP, Nouta J et al (2016) Automated multiplex LC-MS\/MS assay for quantifying serum apolipoproteins A-I, B, C-I, C-II, C-III, and E with qualitative apolipoprotein E phenotyping. Clin Chem 62(1):188\u2013197","journal-title":"Clin Chem"},{"issue":"4","key":"1106_CR23","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1194\/jlr.M700338-JLR200","volume":"49","author":"B Kaess","year":"2008","unstructured":"Kaess B, Fischer M, Baessler A et al (2008) The lipoprotein subfraction profile: heritability and identification of quantitative trait loci. J Lipid Res 49(4):715\u2013723","journal-title":"J Lipid Res"},{"issue":"2","key":"1106_CR24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","volume":"364","author":"AV Khera","year":"2011","unstructured":"Khera AV, Cuchel M, de la Llera-Moya M et al (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364(2):127\u2013135","journal-title":"N Engl J Med"},{"issue":"25","key":"1106_CR25","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","volume":"371","author":"A Rohatgi","year":"2014","unstructured":"Rohatgi A, Khera A, Berry JD et al (2014) HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 371(25):2383\u20132393","journal-title":"N Engl J Med"},{"issue":"19","key":"1106_CR26","first-page":"1870","volume":"372","author":"A Ritsch","year":"2015","unstructured":"Ritsch A, Scharnagl H, Marz W (2015) HDL cholesterol efflux capacity and cardiovascular events. N Engl J Med 372(19):1870\u20131871","journal-title":"N Engl J Med"},{"issue":"21","key":"1106_CR27","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1016\/j.jacc.2016.04.005","volume":"67","author":"W M\u00e4rz","year":"2016","unstructured":"M\u00e4rz W, Ritsch A (2016) Cholesterol efflux capacity: choke point of reverse cholesterol traffic? J Am Coll Cardiol 67(21):2488\u20132491","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1106_CR28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/MOL.0b013e32833c1ef6","volume":"21","author":"EJ Schaefer","year":"2010","unstructured":"Schaefer EJ, Santos RD, Asztalos BF (2010) Marked HDL deficiency and premature coronary heart disease. Curr Opin Lipidol 21(4):289\u2013297","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"1106_CR29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.atherosclerosis.2005.10.033","volume":"186","author":"A Eckardstein von","year":"2006","unstructured":"von Eckardstein A (2006) Differential diagnosis of familial high density lipoprotein deficiency syndromes. Atherosclerosis 186(2):231\u2013239","journal-title":"Atherosclerosis"},{"issue":"8","key":"1106_CR30","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/eurheartj\/ehm066","volume":"28","author":"KM Modesto","year":"2007","unstructured":"Modesto KM, Dispenzieri A, Gertz M et al (2007) Vascular abnormalities in primary amyloidosis. Eur Heart J 28(8):1019\u20131024","journal-title":"Eur Heart J"},{"issue":"7","key":"1106_CR31","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jacc.2004.06.070","volume":"44","author":"GK Hovingh","year":"2004","unstructured":"Hovingh GK, Brownlie A, Bisoendial RJ et al (2004) A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol 44(7):1429\u20131435","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1106_CR32","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.bbalip.2011.08.006","volume":"1821","author":"I Tietjen","year":"2012","unstructured":"Tietjen I, Hovingh GK, Singaraja R et al (2012) Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT. Biochim Biophys Acta 1821(3):416\u2013424","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"1106_CR33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.atherosclerosis.2009.06.005","volume":"208","author":"R Frikke-Schmidt","year":"2010","unstructured":"Frikke-Schmidt R (2010) Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. Atherosclerosis 208(2):305\u2013316","journal-title":"Atherosclerosis"},{"issue":"11","key":"1106_CR34","doi-asserted-by":"crossref","first-page":"e1003063","DOI":"10.1371\/journal.pgen.1003063","volume":"8","author":"CL Haase","year":"2012","unstructured":"Haase CL, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A (2012) Population-based resequencing of APOA1 in 10,330 individuals: spectrum of genetic variation, phenotype, and comparison with extreme phenotype approach. PLoS Genet 8(11):e1003063","journal-title":"PLoS Genet"},{"issue":"7","key":"1106_CR35","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1161\/CIRCULATIONAHA.108.848143","volume":"120","author":"L Calabresi","year":"2009","unstructured":"Calabresi L, Baldassarre D, Castelnuovo S et al (2009) Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation 120(7):628\u2013635","journal-title":"Circulation"},{"issue":"2","key":"1106_CR36","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/CIRCULATIONAHA.108.825109","volume":"120","author":"H Tanigawa","year":"2009","unstructured":"Tanigawa H, Billheimer JT, Tohyama J et al (2009) Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Circulation 120(2):160\u2013169","journal-title":"Circulation"},{"issue":"3","key":"1106_CR37","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/CIRCULATIONAHA.109.875013","volume":"121","author":"A Ritsch","year":"2010","unstructured":"Ritsch A, Scharnagl H, Eller P et al (2010) Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 121(3):366\u2013374","journal-title":"Circulation"},{"issue":"2","key":"1106_CR38","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa0907687","volume":"364","author":"M Vergeer","year":"2011","unstructured":"Vergeer M, Korporaal SJ, Franssen R et al (2011) Genetic variant of the scavenger receptor BI in humans. N Engl J Med 364(2):136\u2013145","journal-title":"N Engl J Med"},{"issue":"12","key":"1106_CR39","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.bbalip.2015.09.006","volume":"1851","author":"SA Ljunggren","year":"2015","unstructured":"Ljunggren SA, Levels JH, Hovingh K et al (2015) Lipoprotein profiles in human heterozygote carriers of a functional mutation P297S in scavenger receptor class B1. Biochim Biophys Acta 1851(12):1587\u20131595","journal-title":"Biochim Biophys Acta"},{"issue":"6278","key":"1106_CR40","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.aad3517","volume":"351","author":"P Zanoni","year":"2016","unstructured":"Zanoni P, Khetarpal SA, Larach DB et al (2016) Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science 351(6278):1166\u20131171","journal-title":"Science"},{"issue":"10","key":"1106_CR41","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1172\/JCI25327","volume":"115","author":"Y Zhang","year":"2005","unstructured":"Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, Rader DJ (2005) Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest 115(10):2870\u20132874","journal-title":"J Clin Invest"},{"issue":"10","key":"1106_CR42","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1172\/JCI26893","volume":"116","author":"T Huby","year":"2006","unstructured":"Huby T, Doucet C, Dachet C et al (2006) Knockdown expression and hepatic deficiency reveal an atheroprotective role for SR-BI in liver and peripheral tissues. J Clin Invest 116(10):2767\u20132776","journal-title":"J Clin Invest"},{"issue":"9841","key":"1106_CR43","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight BF, Peloso GM, Orho-Melander M et al (2012) Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 380(9841):572\u2013580","journal-title":"Lancet"},{"issue":"15","key":"1106_CR44","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","volume":"65","author":"BA Ference","year":"2015","unstructured":"Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD (2015) Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2\u2009\u00d7\u20092 factorial Mendelian randomization study. J Am Coll Cardiol 65(15):1552\u20131561","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1106_CR45","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4093\/dmj.2015.39.5.353","volume":"39","author":"KG Parhofer","year":"2015","unstructured":"Parhofer KG (2015) Interaction between glucose and lipid metabolism: more than diabetic dyslipidemia. Diabetes Metab J 39(5):353\u2013362","journal-title":"Diabetes Metab J"},{"issue":"2","key":"1106_CR46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2015.01.039","volume":"239","author":"MR Taskinen","year":"2015","unstructured":"Taskinen MR, Boren J (2015) New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis 239(2):483\u2013495","journal-title":"Atherosclerosis"},{"issue":"9","key":"1106_CR47","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00392-010-0186-y","volume":"99","author":"EO Gorselen van","year":"2010","unstructured":"van Gorselen EO, Diekman T, Hessels J, Verhorst PM, von Birgelen C (2010) Artifactual measurement of low serum HDL-cholesterol due to paraproteinemia. Clin Res Cardiol Off J Ger Card Soc 99(9):599\u2013602","journal-title":"Clin Res Cardiol Off J Ger Card Soc"},{"issue":"4","key":"1106_CR48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00392-007-0611-z","volume":"97","author":"R Shor","year":"2008","unstructured":"Shor R, Wainstein J, Oz D et al (2008) Low HDL levels and the risk of death, sepsis and malignancy. Clin Res Cardiol Off J Ger Card Soc 97(4):227\u2013233","journal-title":"Clin Res Cardiol Off J Ger Card Soc"},{"key":"1106_CR49","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1172\/JCI114558","volume":"85","author":"JJ Badimon","year":"1990","unstructured":"Badimon JJ, Badimon L, Fuster V (1990) Regression of atherosclerostic lesions by high density lipoprotein lasma fraction in the cholesterol-fed rabbit. J Clin Invest 85:1234\u20131241","journal-title":"J Clin Invest"},{"issue":"4","key":"1106_CR50","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1161\/01.CIR.90.4.1935","volume":"90","author":"S Ameli","year":"1994","unstructured":"Ameli S, Hultgardh-Nilsson A, Cercek B et al (1994) Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 90(4):1935\u20131941","journal-title":"Circulation"},{"issue":"8","key":"1106_CR51","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/01.CIR.97.8.780","volume":"97","author":"PK Shah","year":"1998","unstructured":"Shah PK, Nilsson J, Kaul S et al (1998) Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 97(8):780\u2013785","journal-title":"Circulation"},{"issue":"10","key":"1106_CR52","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1253\/circj.CJ-13-1025","volume":"77","author":"W Annema","year":"2013","unstructured":"Annema W, von Eckardstein A (2013) High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Circ J 77(10):2432\u20132448","journal-title":"Circ J"},{"issue":"1","key":"1106_CR53","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCRESAHA.114.300935","volume":"114","author":"TF Luscher","year":"2014","unstructured":"Luscher TF, Landmesser U, von Eckardstein A, Fogelman AM (2014) High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res 114(1):171\u2013182","journal-title":"Circ Res"},{"issue":"4","key":"1106_CR54","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1172\/JCI200418004","volume":"113","author":"JR Nofer","year":"2004","unstructured":"Nofer JR, van der Giet M, Tolle M et al (2004) HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113(4):569\u2013581","journal-title":"J Clin Invest"},{"issue":"6","key":"1106_CR55","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/ATVBAHA.109.186031","volume":"29","author":"WS Davidson","year":"2009","unstructured":"Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ, Kontush A (2009) Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 29(6):870\u2013876","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1106_CR56","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1172\/JCI26206","volume":"117","author":"T Vaisar","year":"2007","unstructured":"Vaisar T, Pennathur S, Green PS et al (2007) Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117(3):746\u2013756","journal-title":"J Clin Invest"},{"issue":"4","key":"1106_CR57","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ncb2210","volume":"13","author":"KC Vickers","year":"2011","unstructured":"Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13(4):423\u2013433","journal-title":"Nat Cell Biol"},{"issue":"4","key":"1106_CR58","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00041433-200008000-00007","volume":"11","author":"MI Mackness","year":"2000","unstructured":"Mackness MI, Durrington PN, Mackness B (2000) How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol 11(4):383\u2013388","journal-title":"Curr Opin Lipidol"},{"issue":"14","key":"1106_CR59","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jacc.2009.05.061","volume":"54","author":"JJ Regieli","year":"2009","unstructured":"Regieli JJ, Jukema JW, Doevendans PA et al (2009) Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J Am Coll Cardiol 54(14):1238\u20131245","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1106_CR60","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/emmm.201200224","volume":"4","author":"C Besler","year":"2012","unstructured":"Besler C, Luscher TF, Landmesser U (2012) Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med 4(4):251\u2013268","journal-title":"EMBO Mol Med"},{"issue":"1","key":"1106_CR61","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1161\/CIRCULATIONAHA.108.836346","volume":"121","author":"SA Sorrentino","year":"2010","unstructured":"Sorrentino SA, Besler C, Rohrer L et al (2010) Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 121(1):110\u2013122","journal-title":"Circulation"},{"issue":"2","key":"1106_CR62","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1172\/JCI5006","volume":"103","author":"JH Griffin","year":"1999","unstructured":"Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernandez JA (1999) High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 103(2):219\u2013227","journal-title":"J Clin Invest"},{"issue":"15","key":"1106_CR63","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1161\/CIRCULATIONAHA.108.843219","volume":"119","author":"BG Drew","year":"2009","unstructured":"Drew BG, Duffy SJ, Formosa MF et al (2009) High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119(15):2103\u20132111","journal-title":"Circulation"},{"issue":"5","key":"1106_CR64","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1161\/CIRCULATIONAHA.111.018259","volume":"124","author":"PJ Barter","year":"2011","unstructured":"Barter PJ, Rye KA, Tardif JC et al (2011) Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation 124(5):555\u2013562","journal-title":"Circulation"},{"issue":"2","key":"1106_CR65","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1161\/CIRCRESAHA.113.300689","volume":"113","author":"AL Siebel","year":"2013","unstructured":"Siebel AL, Natoli AK, Yap FY et al (2013) Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion. Circ Res 113(2):167\u2013175","journal-title":"Circ Res"},{"issue":"22","key":"1106_CR66","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1161\/CIRCULATIONAHA.113.006345","volume":"128","author":"SP Mortensen","year":"2013","unstructured":"Mortensen SP, Boushel R (2013) High-density lipoprotein: a new therapeutic target for glucose intolerance? Circulation 128(22):2349\u20132350","journal-title":"Circulation"},{"issue":"3","key":"1106_CR67","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/cvr\/cvu143","volume":"103","author":"A Eckardstein von","year":"2014","unstructured":"von Eckardstein A, Widmann C (2014) High-density lipoprotein, beta cells, and diabetes. Cardiovasc Res 103(3):384\u2013394","journal-title":"Cardiovasc Res"},{"issue":"22","key":"1106_CR68","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1161\/CIRCULATIONAHA.113.001551","volume":"128","author":"M Lehti","year":"2013","unstructured":"Lehti M, Donelan E, Abplanalp W et al (2013) High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice. Circulation 128(22):2364\u20132371","journal-title":"Circulation"},{"issue":"12","key":"1106_CR69","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/CIRCRESAHA.113.301684","volume":"113","author":"V Adams","year":"2013","unstructured":"Adams V, Besler C, Fischer T et al (2013) Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties. Circ Res 113(12):1345\u20131355","journal-title":"Circ Res"},{"issue":"7","key":"1106_CR70","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1172\/JCI42946","volume":"121","author":"C Besler","year":"2011","unstructured":"Besler C, Heinrich K, Rohrer L et al (2011) Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 121(7):2693\u20132708","journal-title":"J Clin Invest"},{"issue":"4","key":"1106_CR71","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.immuni.2013.02.009","volume":"38","author":"T Speer","year":"2013","unstructured":"Speer T, Rohrer L, Blyszczuk P et al (2013) Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 38(4):754\u2013768","journal-title":"Immunity"},{"issue":"5","key":"1106_CR72","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.2013050482","volume":"25","author":"S Zewinger","year":"2014","unstructured":"Zewinger S, Speer T, Kleber ME et al (2014) HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J Am Soc Nephrol JASN 25(5):1073\u20131082","journal-title":"J Am Soc Nephrol JASN"},{"issue":"5","key":"1106_CR73","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1681\/ASN.2011070668","volume":"23","author":"T Weichhart","year":"2012","unstructured":"Weichhart T, Kopecky C, Kubicek M et al (2012) Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol JASN 23(5):934\u2013947","journal-title":"J Am Soc Nephrol JASN"},{"issue":"46","key":"1106_CR74","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1093\/eurheartj\/eht343","volume":"34","author":"G Silbernagel","year":"2013","unstructured":"Silbernagel G, Schottker B, Appelbaum S et al (2013) High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. Eur Heart J 34(46):3563\u20133571","journal-title":"Eur Heart J"},{"issue":"8","key":"1106_CR75","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/CIRCULATIONAHA.112.108753","volume":"127","author":"M Riwanto","year":"2013","unstructured":"Riwanto M, Rohrer L, Roschitzki B et al (2013) Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 127(8):891\u2013904","journal-title":"Circulation"},{"issue":"9","key":"1106_CR76","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1172\/JCI67478","volume":"123","author":"Y Huang","year":"2013","unstructured":"Huang Y, Wu Z, Riwanto M et al (2013) Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 123(9):3815\u20133828","journal-title":"J Clin Invest"},{"issue":"43","key":"1106_CR77","first-page":"3007","volume":"36","author":"S Zewinger","year":"2015","unstructured":"Zewinger S, Drechsler C, Kleber ME et al (2015) Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. Eur Heart J 36(43):3007\u20133016","journal-title":"Eur Heart J"},{"issue":"7","key":"1106_CR78","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1161\/ATVBAHA.113.301373","volume":"33","author":"XM Li","year":"2013","unstructured":"Li XM, Tang WH, Mosior MK et al (2013) Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 33(7):1696\u20131705","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"1106_CR79","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jama.298.7.786","volume":"298","author":"IM Singh","year":"2007","unstructured":"Singh IM, Shishehbor MH, Ansell BJ (2007) High-density lipoprotein as a therapeutic target: a systematic review. JAMA 298(7):786\u2013798","journal-title":"JAMA"},{"issue":"25 Suppl 2","key":"1106_CR80","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1161\/01.cir.0000437740.48606.d1","volume":"129","author":"RH Eckel","year":"2013","unstructured":"Eckel RH, Jakicic JM, Ard JD, et al (2013) AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl 2):S76\u2013S99","journal-title":"Circulation"},{"issue":"5","key":"1106_CR81","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.orcp.2015.10.010","volume":"10","author":"M Cai","year":"2016","unstructured":"Cai M, Zou Z (2016) Effect of aerobic exercise on blood lipid and glucose in obese or overweight adults: a meta-analysis of randomised controlled trials. Obes Res Clin Pract 10(5):589\u2013602. doi: 10.1016\/j.orcp.2015.10.010","journal-title":"Obes Res Clin Pract"},{"issue":"6","key":"1106_CR82","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1210\/jc.2015-1196","volume":"100","author":"K Ghafouri","year":"2015","unstructured":"Ghafouri K, Cooney J, Bedford DK, Wilson J, Caslake MJ, Gill JM (2015) Moderate exercise increases affinity of large very low-density lipoproteins for hydrolysis by lipoprotein lipase. J Clin Endocrinol Metab 100(6):2205\u20132213","journal-title":"J Clin Endocrinol Metab"},{"key":"1106_CR83","doi-asserted-by":"crossref","first-page":"b92","DOI":"10.1136\/bmj.b92","volume":"338","author":"M Briel","year":"2009","unstructured":"Briel M, Ferreira-Gonzalez I, You JJ et al (2009) Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338:b92","journal-title":"BMJ"},{"key":"1106_CR84","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-016-1069-7","author":"H Soran","year":"2017","unstructured":"Soran H, Dent R, Durrington P (2017) Evidence-based goals in LDL-C reduction. Clin Res Cardiol. doi: 10.1007\/s00392-016-1069-7","journal-title":"Clin Res Cardiol"},{"issue":"9","key":"1106_CR85","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00392-016-0991-z","volume":"105","author":"U Laufs","year":"2016","unstructured":"Laufs U, Karmann B, Pittrow D (2016) Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. Clin Res Cardiol Off J Ger Card Soc 105(9):783\u2013790","journal-title":"Clin Res Cardiol Off J Ger Card Soc"},{"issue":"9729","key":"1106_CR86","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","volume":"375","author":"M Jun","year":"2010","unstructured":"Jun M, Foote C, Lv J et al (2010) Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375(9729):1875\u20131884","journal-title":"Lancet"},{"issue":"9500","key":"1106_CR87","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P et al (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500):1849\u20131861","journal-title":"Lancet"},{"issue":"17","key":"1106_CR88","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"Ginsberg HN, Elam MB, Lovato LC et al (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362(17):1563\u20131574","journal-title":"N Engl J Med"},{"issue":"9677","key":"1106_CR89","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","volume":"373","author":"K Rajamani","year":"2009","unstructured":"Rajamani K, Colman PG, Li LP et al (2009) Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 373(9677):1780\u20131788","journal-title":"Lancet"},{"issue":"8","key":"1106_CR90","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1185\/03007995.2010.489341","volume":"26","author":"JC Fruchart","year":"2010","unstructured":"Fruchart JC, Sacks FM, Hermans MP (2010) Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i). Curr Med Res Opin 26(8):1793\u20131797","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1106_CR91","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","volume":"57","author":"E Bruckert","year":"2011","unstructured":"Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P (2011) Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol 57(2):267\u2013272","journal-title":"J Cardiovasc Pharmacol"},{"issue":"24","key":"1106_CR92","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"WE Boden","year":"2011","unstructured":"Boden WE, Probstfield JL, Anderson T et al (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365(24):2255\u20132267","journal-title":"N Engl J Med"},{"issue":"2","key":"1106_CR93","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2009.12.023","volume":"210","author":"E Bruckert","year":"2010","unstructured":"Bruckert E, Labreuche J, Amarenco P (2010) Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210(2):353\u2013361","journal-title":"Atherosclerosis"},{"issue":"4","key":"1106_CR94","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jacc.2012.10.030","volume":"61","author":"PM Lavigne","year":"2013","unstructured":"Lavigne PM, Karas RH (2013) The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol 61(4):440\u2013446","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1106_CR95","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"MJ Landray","year":"2014","unstructured":"Landray MJ, Haynes R, Hopewell JC et al (2014) Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371(3):203\u2013212","journal-title":"N Engl J Med"},{"key":"1106_CR96","unstructured":"Administration FaD (2016) Withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended-release tablets and fenofibric acid delayed-release capsules. Fed Reg 81(74)"},{"key":"1106_CR97","unstructured":"Administration FaD (2016) Withdrawal of approval of new drug applications for Advicor and Simcor. Fed Reg 81(74)"},{"issue":"2","key":"1106_CR98","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-2275(20)39898-9","volume":"36","author":"CJ Fielding","year":"1995","unstructured":"Fielding CJ, Fielding PE (1995) Molecular physiology of reverse cholesterol transport. J Lipid Res 36(2):211\u2013228","journal-title":"J Lipid Res"},{"issue":"8","key":"1106_CR99","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0022-2275(20)36957-1","volume":"34","author":"AR Tall","year":"1993","unstructured":"Tall AR (1993) Plasma cholesteryl ester transfer protein. J Lipid Res 34(8):1255\u20131274","journal-title":"J Lipid Res"},{"issue":"20","key":"1106_CR100","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.jacc.2012.07.045","volume":"60","author":"TH Johannsen","year":"2012","unstructured":"Johannsen TH, Frikke-Schmidt R, Schou J, Nordestgaard BG, Tybjaerg-Hansen A (2012) Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J Am Coll Cardiol 60(20):2041\u20132048","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1106_CR101","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s11033-012-2257-9","volume":"40","author":"YY Li","year":"2013","unstructured":"Li YY, Wu XY, Xu J, Qian Y, Zhou CW, Wang B (2013) Apo A5 -1131\u00a0T\/C, FgB \u2013 455G\/A, -148C\/T, and CETP TaqIB gene polymorphisms and coronary artery disease in the Chinese population: a meta-analysis of 15,055 subjects. Mol Biol Rep 40(2):1997\u20132014","journal-title":"Mol Biol Rep"},{"issue":"1","key":"1106_CR102","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCGENETICS.114.000748","volume":"8","author":"W Niu","year":"2015","unstructured":"Niu W, Qi Y (2015) Circulating cholesteryl ester transfer protein and coronary heart disease: Mendelian randomization meta-analysis. Circ Cardiovasc Genet 8(1):114\u2013121","journal-title":"Circ Cardiovasc Genet"},{"issue":"5","key":"1106_CR103","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/CIRCULATIONAHA.115.014026","volume":"132","author":"GK Hovingh","year":"2015","unstructured":"Hovingh GK, Ray KK, Boekholdt SM (2015) Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk? CETP as a target to lower CVD risk: suspension of disbelief? Circulation 132(5):433\u2013440","journal-title":"Circulation"},{"issue":"15","key":"1106_CR104","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJMoa031766","volume":"350","author":"ME Brousseau","year":"2004","unstructured":"Brousseau ME, Schaefer EJ, Wolfe ML et al (2004) Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350(15):1505\u20131515","journal-title":"N Engl J Med"},{"issue":"11 A","key":"1106_CR105","doi-asserted-by":"crossref","first-page":"n47","DOI":"10.1016\/j.amjcard.2007.08.013","volume":"100","author":"JJ Kastelein","year":"2007","unstructured":"Kastelein JJ (2007) Refocusing on use of cholesteryl ester transfer protein inhibitors. Am J Cardiol 100(11 A):n47\u2013n52","journal-title":"Am J Cardiol"},{"issue":"21","key":"1106_CR106","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M et al (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357(21):2109\u20132122","journal-title":"N Engl J Med"},{"issue":"22","key":"1106_CR107","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","volume":"367","author":"GG Schwartz","year":"2012","unstructured":"Schwartz GG, Olsson AG, Abt M et al (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367(22):2089\u20132099","journal-title":"N Engl J Med"},{"issue":"3","key":"1106_CR108","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/MOL.0000000000000294","volume":"27","author":"A Eckardstein von","year":"2016","unstructured":"von Eckardstein A, Rohrer L (2016) HDLs in crises. Curr Opin Lipidol 27(3):264\u2013273","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"1106_CR109","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1194\/jlr.M056333","volume":"56","author":"RE Morton","year":"2015","unstructured":"Morton RE, Izem L (2015) Modification of CETP function by changing its substrate preference: a new paradigm for CETP drug design. J Lipid Res 56(3):612\u2013619","journal-title":"J Lipid Res"},{"key":"1106_CR110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.atherosclerosissup.2015.02.020","volume":"18","author":"KG Parhofer","year":"2015","unstructured":"Parhofer KG (2015) Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective. Atheroscler Suppl 18:109\u2013111","journal-title":"Atheroscler Suppl"},{"issue":"6","key":"1106_CR111","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrd4279","volume":"13","author":"BA Kingwell","year":"2014","unstructured":"Kingwell BA, Chapman MJ, Kontush A, Miller NE (2014) HDL-targeted therapies: progress, failures and future. Nat Rev Drug Discov 13(6):445\u2013464","journal-title":"Nat Rev Drug Discov"},{"key":"1106_CR112","unstructured":"Nicholls SJ, Nissen SE, Kallend D, Winjgaard P, Borgman M (2016) Impact of infusion of an ApoA-I-Milano HDL mimetic on regression of coronary atherosclerosis in acute coronary syndrome patients: the MILANO-PILOT Study. American Heart Association Scientific Sessions 2016, New Orleans, Louisiana, USA, Nov 12\u201316. http:\/\/www.abstractsonline.com\/pp8\/#!\/4096\/presentation\/58822 . Accessed 21 March 2017"},{"issue":"1","key":"1106_CR113","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40256-015-0146-z","volume":"16","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Wolski K et al (2016) Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the Phase 2b, randomized, double-blind, multicenter, ASSURE Trial. Am J Cardiovasc Drugs Drugs Devices Other Interv 16(1):55\u201365","journal-title":"Am J Cardiovasc Drugs Drugs Devices Other Interv"},{"issue":"46","key":"1106_CR114","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","volume":"35","author":"JC Tardif","year":"2014","unstructured":"Tardif JC, Ballantyne CM, Barter P et al (2014) Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J 35(46):3277\u20133286","journal-title":"Eur Heart J"},{"issue":"5","key":"1106_CR115","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/HCO.0000000000000211","volume":"30","author":"HK Siddiqi","year":"2015","unstructured":"Siddiqi HK, Kiss D, Rader D (2015) HDL-cholesterol and cardiovascular disease: rethinking our approach. Curr Opin Cardiol 30(5):536\u2013542","journal-title":"Curr Opin Cardiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-017-1106-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-017-1106-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-017-1106-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T21:34:18Z","timestamp":1658871258000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-017-1106-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,24]]},"references-count":115,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["1106"],"URL":"https:\/\/doi.org\/10.1007\/s00392-017-1106-1","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,24]]}}}